1:15 PM
Feb 13, 2018
 |  BC Extra  |  Company News

EC approves Diurnal's Alkindi

Diurnal Group plc (LSE:DNL) said the European Commission approved Alkindi (Infacort) as a replacement therapy to treat adrenal insufficiency in individuals less than 18 years old. Diurnal plans to launch Alkindi in 2Q18, but told BioCentury it was "too early" to discuss pricing.

Alkindi is a dry granule formulation of hydrocortisone.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD